(Q42693300)

English

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

scientific article published on 13 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer (English)

1 reference

Europe PubMed Central

4 November 2017

phase III clinical trial

0 references

Fiona Blackhall

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Igor N. Bondarenko

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Janusz Milanowski

7

object named as

J Milanowski

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

G V Scagliotti

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

F Barlesi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

T-C Hsia

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

J M Sanchez-Torres

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

S Novello

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

R J Benner

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

S Green

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

K Molpus

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

J-C Soria

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

F A Shepherd

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

13 November 2014

1 reference

Europe PubMed Central

4 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

497-504

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395283%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU517

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42693300&oldid=2111277185"